Transforming cancer treatment and advancing new therapies through empowered science

Corporate Profile

Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells.

The company’s lead product, ADCETRIS® (brentuximab vedotin) is an ADC that, in collaboration with Takeda Pharmaceutical Company Limited is commercially available for two indications in more than 45 countries, including the U.S., Canada, Japan and members of the European Union. Additionally, ADCETRIS is being evaluated broadly in more than 30 ongoing clinical trials. Seattle Genetics is also advancing a robust pipeline of clinical-stage ADC programs designed to address the unmet medical needs of people with cancer, including SGN-CD19A, SGN-CD33A, SGN-LIV1A, SGN-CD70A, ASG-22ME and ASG-15ME. Seattle Genetics’ ADC technology is employed by a number of leading biotechnology and pharmaceutical companies, including AbbVie, Agensys (an affiliate of Astellas), Bayer, Genentech, GlaxoSmithKline and Pfizer. Across both internal and collaborator programs, there are 25 ADCs in clinical development using our proprietary approach to empowering antibodies.

Download Documentation  Corporate Fact Sheet
Download Documentation  2013 Annual Report
Download Documentation  2014 Proxy Statement
Investor Contact
Peggy Pinkston
Senior Director, Corporate Communications
PHONE: (425) 527-4160
FAX: (425) 527-4001
EMAIL: ppinkston@seagen.com

Media Contact
Tricia Larson
Director, Public Relations
PHONE: 425-527-4180
EMAIL: tlarson@seagen.com
Stock Quote
SGEN (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$32.00
Change (%) Stock is Up 0.90 (2.89%)
Volume856,299
Data as of 12/26/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >
DateTitle 
12/18/14Seattle Genetics Initiates Phase 1b Trial of SGN-CD33A in Combination with Frontline Standard of Care and as Consolidation Therapy for Acute Myeloid Leukemia
-SGN-CD33A is an Antibody-Drug Conjugate (ADC) Utilizing Seattle Genetics’ Newest ADC Technology- BOTHELL, Wash.--(BUSINESS WIRE)--Dec. 18, 2014-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced initiation of a phase 1b clinical trial of SGN-CD33A in combination with standard of care chemotherapy, including cytarabine and daunorubicin, for patients with newly diagnosed acute myeloid leukemia (AML). The trial will also evaluate SGN... 
Printer Friendly Version
12/08/14Seattle Genetics Presents Data from Novel Antibody-Drug Conjugate SGN-CD33A at ASH Annual Meeting
First Clinical Data Presentation of SGN-CD33A Demonstrates Encouraging Antitumor Activity in Acute Myeloid Leukemia; Dose and Schedule Refinement Ongoing Phase 1b Combination Trial Planned to Evaluate SGN-CD33A with Standard of Care in Frontline and Consolidation Settings for Acute Myeloid Leukemia SAN FRANCISCO--(BUSINESS WIRE)--Dec. 8, 2014-- Seattle Genetics, Inc. (Nasdaq:SGEN) today presented data from an ongoing phas... 
Printer Friendly Version
12/08/14Seattle Genetics Presents ADCETRIS® (Brentuximab Vedotin) Data in Diffuse Large B-cell Lymphoma at ASH Annual Meeting
-ADCETRIS Demonstrates Antitumor Activity in Both CD30-Positive and CD30-Undetectable Relapsed/Refractory DLBCL- -Phase 2 Randomized Trial Planned for Relapsed/Refractory CD30-Positive DLBCL- -ADCETRIS in Combination with RCHOP for Frontline DLBCL Shows High Complete Response Rate and Manageable Safety Profile- SAN FRANCISCO--(BUSINESS WIRE)--Dec. 8, 2014-- Seattle Genetics, Inc. (Nasdaq: SGEN) today highlighted two sepa... 
Printer Friendly Version
12/08/14Seattle Genetics Highlights Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations in Frontline and Salvage Hodgkin Lymphoma at ASH Annual Meeting
-Long-Term Data from Phase 1 Trial of ADCETRIS Combined with AVD in Frontline Hodgkin Lymphoma Demonstrate 100 Percent Three-Year Overall Survival Rate and 92 Percent Three-Year Failure-Free Survival Rate; Data Provide Continued Strong Support for ECHELON-1 Trial- -ADCETRIS in Combination with Bendamustine in Relapsed or Refractory Hodgkin Lymphoma as Second-line Therapy Shows Objective Response Rate of 96 Percent and Complete Remission Rate of 8... 
Printer Friendly Version
12/07/14Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting
-Estimated Four-Year Survival Rate of 64 Percent- -Half of Patients who Achieved Complete Remission Remain Disease-free- SAN FRANCISCO, CA, December 7, 2014– Seattle Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced four-year overall survival (OS) data from the ADCETRIS (brentuximab vedotin) pivotal Phase 2 clinical trial in relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). ADCETRIS is an antibody-drug conjugate (... 
Printer Friendly Version
Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.